More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings (-30.4% Growth)
- Ratings (4.1 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/29/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements
Licensing and royalty revenue
Total revenue 36.87M
Research and development
General and administrative 10.56M
Total operating expenses 91.53M
Loss from operations -54.65M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 1.46M
Interest expense -9.49M
Gain (loss) on investments, net
Loss before income tax expense
Income tax expense -232K
Net loss -62.92M
Basic net loss (in dollars per share)
Diluted net loss (in dollars per share)
Shares used in computing basic net loss per share (in shares)
Shares used in computing diluted net loss per share (in shares)